ABSTRACT
Since the evolution of coronary stenting, both stent thrombosis, the development of a platelet and fibrin clot on the endothelial metal prosthesis, in stent restenosis (ISR) and the variable neo-endothelialisation of the stent platform, have been observed. Stent thrombosis, as defined by the academic research consortium (ARC) in 2007, is the angiographic or pathological total or partial thrombotic occlusion within a stent that is associated with ischemic symptoms, electrocardiogram (ECG) changes or elevated cardiac biomarkers. Stent thrombosis can present in a variety of ways, though typically the patient will experience symptoms of ischemia, ECG changes and biomarker elevations consistent with an acute myocardial infarction. Early stent thrombosis occurs within 30 days after stent implantation, and is usually secondary to technical and procedural factors. Stent underexpansion occurs when an undersized stent is selected for the target vessel or when the arterial wall does not allow for full expansion of the stent at the time of initial implantation.
